Chemotherapy Device Market by Product Type (Catheters, Implantable Ports, Infusion Pumps), Modality (Portable Devices, Stationary Devices), Application, End User - Global Forecast 2025-2032
Description
The Chemotherapy Device Market was valued at USD 3.58 billion in 2024 and is projected to grow to USD 3.84 billion in 2025, with a CAGR of 7.46%, reaching USD 6.38 billion by 2032.
A comprehensive framing of the chemotherapy delivery device landscape that explains clinical priorities, technological levers, and strategic questions for stakeholders
The contemporary chemotherapy device landscape sits at the intersection of rapid clinical innovation, heightened patient-centric care models, and increasingly complex supply chains. Recent advances in device materials, infusion technology, and closed-system connectors have expanded therapeutic options while simultaneously raising expectations for safety, usability, and interoperability. Healthcare providers demand devices that reduce infusion errors, lower infection risk, and enable outpatient or home-based care, and device manufacturers are responding with modular designs, simplified interfaces, and integrated monitoring capabilities.
As a result, stakeholders across the ecosystem - clinical teams, procurement officers, regulators, and manufacturers - must navigate a shifting balance between clinical efficacy, cost containment, and regulatory compliance. This introduction frames the broader context for the subsequent analysis by outlining the core drivers of change, clarifying the types of devices under consideration, and establishing the strategic questions that decision-makers should prioritize when assessing product portfolios and market entry strategies. By setting this foundation, readers will better appreciate how technological, clinical, and policy dynamics converge to shape device-level choices and commercial pathways.
How technological integration, outpatient care trends, and regulatory emphasis on safety and connectivity are redefining development and commercialization strategies
The landscape for chemotherapy delivery devices is experiencing transformative shifts driven by technology integration, care model decentralization, and regulatory emphasis on safety and data interoperability. Innovations in infusion pump control algorithms, elastomeric device design, and needleless connectors are improving dosing precision and reducing user dependency, which in turn supports movement away from inpatient administration toward ambulatory surgical centers and homecare settings. These transitions are reinforced by workforce pressures, patient preferences for outpatient care, and payer interest in value-based pathways that reward lower complication rates and reduced length of stay.
Concurrently, digital health integration is changing device lifecycles. Connectivity enables remote monitoring, predictive maintenance, and integration with electronic health records, which enhances clinician oversight but introduces new requirements for cybersecurity and data governance. Manufacturers are therefore investing in secure firmware, standardized communication protocols, and post-market surveillance systems to demonstrate device reliability and to meet evolving regulatory expectations. Taken together, these shifts compel both established companies and emerging entrants to re-evaluate product design priorities, commercialization models, and partnerships with service providers to remain relevant in a rapidly modernizing care environment.
Assessing the 2025 trade measures and tariffs to understand their cascading effects on procurement choices, supplier strategies, and manufacturing localization decisions
The introduction of new tariffs and trade measures in 2025 has exerted a multifaceted impact on the chemotherapy device value chain, with consequences that extend beyond immediate cost pressures. Component sourcing, particularly for precision plastics, microfluidic elements, and electronic control modules, has become more strategic as manufacturers reassess supplier footprints to mitigate exposure to import duties. In response, some firms have moved toward diversified supplier networks and regional procurement strategies to preserve margin and minimize disruption to product availability.
Moreover, the tariff environment has accelerated conversations about manufacturing localization and vertical integration. While reshoring or nearshoring can reduce tariff exposure and shorten lead times, these moves also entail capital investment, workforce development, and regulatory recertification burdens. At the same time, providers and purchasing consortia are adapting contracting approaches to account for supplier cost volatility, seeking longer-term agreements and greater transparency around component origin. Collectively, these dynamics influence product roadmaps, pricing strategies, and partnership models, prompting manufacturers and health systems to balance agility with investment in supply chain resilience.
Deconstructing the chemotherapy device market through product, modality, application, and end-user segmentation to reveal clinical fit and commercial opportunity
Segmentation analysis offers a structured lens for interpreting demand drivers and clinical fit across device categories and care settings. Based on Product Type, the device landscape includes Catheters, Implantable Ports, Infusion Pumps, and Needleless Connectors, and the Catheters category further differentiates into Central Venous Catheters and Peripheral Catheters while Infusion Pumps subdivide into Elastomeric Pumps, Syringe Pumps, and Volumetric Pumps; this granularity highlights where clinical preferences and procedural protocols create distinct performance and regulatory expectations. For example, central venous access devices and implantable ports remain central to long-term infusion therapy, whereas peripheral catheters and portable elastomeric pumps enable shorter-term or home-based regimens, which demands a different emphasis on ease of use and patient education.
Based on Modality, devices are segmented into Portable Devices and Stationary Devices, and this distinction matters for adoption patterns: portable offerings support outpatient and homecare expansion and require robust user-centric design and simplified maintenance, while stationary devices continue to dominate in high-acuity hospital settings where advanced functionality and integration with institutional workflows are priorities. Based on Application, clinical need is framed across Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, and Prostate Cancer, with each indication exerting unique requirements for infusion duration, vascular access stability, and toxicity management. Finally, Based on End User, adoption channels encompass Ambulatory Surgical Centers, Homecare Settings, and Hospitals & Clinics, and aligning product features with the operational capabilities of these environments is essential for commercial success. Integrating these segmentation perspectives reveals product development gaps and commercialization opportunities where device design, training programs, and service models can be optimized to meet the nuanced demands of different clinical scenarios and care delivery sites.
Understanding how regional regulatory environments, care delivery models, and supply chain structures shape adoption and market entry priorities across global markets
Regional dynamics materially influence regulatory pathways, procurement practices, and clinical adoption patterns for chemotherapy delivery devices. In the Americas, clinical systems emphasize consolidation, centralized purchasing, and the adoption of outpatient infusion models, driving demand for devices that reduce complications and support shorter hospital stays; regional reimbursement frameworks and supply chain networks shape pricing strategies and rollout timelines. In Europe, Middle East & Africa, heterogeneity in regulatory regimes and healthcare infrastructure creates a landscape where adaptable device designs and flexible distribution models are advantageous, allowing manufacturers to tailor market entry approaches and post-market support to local needs.
Asia-Pacific presents a distinct mix of rapid infrastructure investment, growing oncology caseloads, and a rising appetite for locally manufactured or regionally certified devices, which can accelerate uptake when combined with training initiatives and collaborative clinical studies. Across all regions, regulatory scrutiny on device safety, sterilization practices, and connectivity compliance is increasing, so aligning product development and quality systems with regional regulatory expectations reduces market access friction. Understanding these geographic nuances enables companies to prioritize investments and to sequence product introductions for maximal clinical and commercial impact.
Mapping competitive roles and partnership models to illuminate how incumbents, specialists, and manufacturing partners shape product differentiation and market access
Competitive dynamics in the chemotherapy device space reflect a mix of incumbent manufacturers with broad portfolios, specialized innovators focused on discrete device classes, and contract manufacturers that enable scale or rapid iterations. Incumbents often leverage established clinical relationships, broad distribution networks, and post-market surveillance capabilities to sustain preference among health systems, while niche players concentrate on design differentiation such as low-profile implantable ports, advanced catheter coatings, or compact elastomeric pump form factors that address clinician and patient pain points. Contract manufacturers and assembly partners play a pivotal role in accelerating time-to-market by providing regulatory-compliant manufacturing environments and supply chain continuity.
Strategic alliances between device companies, infusion therapy service providers, and digital health vendors are emerging to create integrated solutions that combine hardware, consumables, and cloud-enabled monitoring. At the same time, regulatory compliance and quality management remain decisive competitive levers; firms that demonstrate robust safety performance, transparent post-market data, and streamlined regulatory submissions gain credibility with procurement committees. Overall, competitiveness derives less from single-product superiority and more from the ability to deliver comprehensive, supportable, and economically viable solutions across clinical pathways.
Actionable strategic priorities for device makers and healthcare providers to accelerate adoption, strengthen supply chains, and enhance long-term competitiveness
Industry leaders must pursue a set of coordinated actions to translate technological progress and market signals into sustained commercial advantage. First, align product development with real-world clinical workflows by investing in human factors research and clinician co-design efforts; devices that fit seamlessly into nursing routines and caregiver tasks reduce training burden and accelerate adoption. Second, prioritize supply chain resilience through supplier diversification, strategic inventory buffers for critical components, and scenario-based contingency planning to withstand trade disruptions and material shortages.
Third, embed connectivity and cybersecurity by design, ensuring that devices offer secure telemetry and interoperability while meeting patient privacy expectations and regulatory requirements. Fourth, adopt flexible commercialization models that combine capital sales with service or managed-use offerings, enabling providers to control upfront costs while benefitting from ongoing maintenance and analytics. Fifth, engage early with regional regulatory authorities to streamline approvals and align post-market surveillance programs with local expectations. Taken together, these actions create a defensible value proposition and reduce commercial risk while positioning organizations to respond to evolving clinical and policy environments.
A robust mixed-methods research design integrating stakeholder interviews, observational validation, regulatory review, and supply chain mapping for rigorous insights
The research methodology underpinning this analysis combines primary stakeholder engagement, comprehensive secondary review, and structured synthesis to ensure rigor and relevance. Primary research involved qualitative interviews with clinicians, procurement leaders, regulatory specialists, and device engineers to capture frontline perspectives on usability, failure modes, and procurement decision criteria. These insights were supplemented by observational assessments of infusion workflows and device handling practices to validate reported pain points and to identify latent design needs.
Secondary research encompassed regulatory documentation, standards guidance, patent landscapes, and clinical literature to map safety requirements, technological trajectories, and evidence expectations. Data triangulation techniques reconciled differing inputs, enabling the identification of consistent themes and outliers. The methodology also incorporated supply chain mapping and risk assessment to evaluate sourcing exposure and logistics constraints. Throughout, quality controls included expert peer review, traceability of primary data sources, and iterative validation with independent subject matter experts to ensure that conclusions reflect both empirical observation and domain expertise.
Concluding synthesis that connects device innovation, supply chain resilience, and regulatory strategy to long-term clinical and commercial value creation
In conclusion, the chemotherapy device ecosystem is in a period of constructive disruption driven by clinical decentralization, device connectivity, and supply chain recalibration. These forces create opportunities for product innovation that prioritizes patient safety, clinician usability, and flexible deployment across ambulatory, homecare, and institutional settings. Trade-related developments have added urgency to supply chain strategy and sourcing decisions, prompting firms to evaluate localization, supplier diversification, and contract structures as means to preserve continuity and margin.
Decision-makers who combine human-centered design, integrated digital capabilities, and proactive regulatory engagement will be best positioned to translate technical advances into sustained clinical and commercial value. By focusing on resilient operations and solution-oriented commercialization, manufacturers and providers can adapt to current headwinds and capitalize on the evolving modalities of cancer care to deliver safer, more accessible infusion therapies.
Note: PDF & Excel + Online Access - 1 Year
A comprehensive framing of the chemotherapy delivery device landscape that explains clinical priorities, technological levers, and strategic questions for stakeholders
The contemporary chemotherapy device landscape sits at the intersection of rapid clinical innovation, heightened patient-centric care models, and increasingly complex supply chains. Recent advances in device materials, infusion technology, and closed-system connectors have expanded therapeutic options while simultaneously raising expectations for safety, usability, and interoperability. Healthcare providers demand devices that reduce infusion errors, lower infection risk, and enable outpatient or home-based care, and device manufacturers are responding with modular designs, simplified interfaces, and integrated monitoring capabilities.
As a result, stakeholders across the ecosystem - clinical teams, procurement officers, regulators, and manufacturers - must navigate a shifting balance between clinical efficacy, cost containment, and regulatory compliance. This introduction frames the broader context for the subsequent analysis by outlining the core drivers of change, clarifying the types of devices under consideration, and establishing the strategic questions that decision-makers should prioritize when assessing product portfolios and market entry strategies. By setting this foundation, readers will better appreciate how technological, clinical, and policy dynamics converge to shape device-level choices and commercial pathways.
How technological integration, outpatient care trends, and regulatory emphasis on safety and connectivity are redefining development and commercialization strategies
The landscape for chemotherapy delivery devices is experiencing transformative shifts driven by technology integration, care model decentralization, and regulatory emphasis on safety and data interoperability. Innovations in infusion pump control algorithms, elastomeric device design, and needleless connectors are improving dosing precision and reducing user dependency, which in turn supports movement away from inpatient administration toward ambulatory surgical centers and homecare settings. These transitions are reinforced by workforce pressures, patient preferences for outpatient care, and payer interest in value-based pathways that reward lower complication rates and reduced length of stay.
Concurrently, digital health integration is changing device lifecycles. Connectivity enables remote monitoring, predictive maintenance, and integration with electronic health records, which enhances clinician oversight but introduces new requirements for cybersecurity and data governance. Manufacturers are therefore investing in secure firmware, standardized communication protocols, and post-market surveillance systems to demonstrate device reliability and to meet evolving regulatory expectations. Taken together, these shifts compel both established companies and emerging entrants to re-evaluate product design priorities, commercialization models, and partnerships with service providers to remain relevant in a rapidly modernizing care environment.
Assessing the 2025 trade measures and tariffs to understand their cascading effects on procurement choices, supplier strategies, and manufacturing localization decisions
The introduction of new tariffs and trade measures in 2025 has exerted a multifaceted impact on the chemotherapy device value chain, with consequences that extend beyond immediate cost pressures. Component sourcing, particularly for precision plastics, microfluidic elements, and electronic control modules, has become more strategic as manufacturers reassess supplier footprints to mitigate exposure to import duties. In response, some firms have moved toward diversified supplier networks and regional procurement strategies to preserve margin and minimize disruption to product availability.
Moreover, the tariff environment has accelerated conversations about manufacturing localization and vertical integration. While reshoring or nearshoring can reduce tariff exposure and shorten lead times, these moves also entail capital investment, workforce development, and regulatory recertification burdens. At the same time, providers and purchasing consortia are adapting contracting approaches to account for supplier cost volatility, seeking longer-term agreements and greater transparency around component origin. Collectively, these dynamics influence product roadmaps, pricing strategies, and partnership models, prompting manufacturers and health systems to balance agility with investment in supply chain resilience.
Deconstructing the chemotherapy device market through product, modality, application, and end-user segmentation to reveal clinical fit and commercial opportunity
Segmentation analysis offers a structured lens for interpreting demand drivers and clinical fit across device categories and care settings. Based on Product Type, the device landscape includes Catheters, Implantable Ports, Infusion Pumps, and Needleless Connectors, and the Catheters category further differentiates into Central Venous Catheters and Peripheral Catheters while Infusion Pumps subdivide into Elastomeric Pumps, Syringe Pumps, and Volumetric Pumps; this granularity highlights where clinical preferences and procedural protocols create distinct performance and regulatory expectations. For example, central venous access devices and implantable ports remain central to long-term infusion therapy, whereas peripheral catheters and portable elastomeric pumps enable shorter-term or home-based regimens, which demands a different emphasis on ease of use and patient education.
Based on Modality, devices are segmented into Portable Devices and Stationary Devices, and this distinction matters for adoption patterns: portable offerings support outpatient and homecare expansion and require robust user-centric design and simplified maintenance, while stationary devices continue to dominate in high-acuity hospital settings where advanced functionality and integration with institutional workflows are priorities. Based on Application, clinical need is framed across Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, and Prostate Cancer, with each indication exerting unique requirements for infusion duration, vascular access stability, and toxicity management. Finally, Based on End User, adoption channels encompass Ambulatory Surgical Centers, Homecare Settings, and Hospitals & Clinics, and aligning product features with the operational capabilities of these environments is essential for commercial success. Integrating these segmentation perspectives reveals product development gaps and commercialization opportunities where device design, training programs, and service models can be optimized to meet the nuanced demands of different clinical scenarios and care delivery sites.
Understanding how regional regulatory environments, care delivery models, and supply chain structures shape adoption and market entry priorities across global markets
Regional dynamics materially influence regulatory pathways, procurement practices, and clinical adoption patterns for chemotherapy delivery devices. In the Americas, clinical systems emphasize consolidation, centralized purchasing, and the adoption of outpatient infusion models, driving demand for devices that reduce complications and support shorter hospital stays; regional reimbursement frameworks and supply chain networks shape pricing strategies and rollout timelines. In Europe, Middle East & Africa, heterogeneity in regulatory regimes and healthcare infrastructure creates a landscape where adaptable device designs and flexible distribution models are advantageous, allowing manufacturers to tailor market entry approaches and post-market support to local needs.
Asia-Pacific presents a distinct mix of rapid infrastructure investment, growing oncology caseloads, and a rising appetite for locally manufactured or regionally certified devices, which can accelerate uptake when combined with training initiatives and collaborative clinical studies. Across all regions, regulatory scrutiny on device safety, sterilization practices, and connectivity compliance is increasing, so aligning product development and quality systems with regional regulatory expectations reduces market access friction. Understanding these geographic nuances enables companies to prioritize investments and to sequence product introductions for maximal clinical and commercial impact.
Mapping competitive roles and partnership models to illuminate how incumbents, specialists, and manufacturing partners shape product differentiation and market access
Competitive dynamics in the chemotherapy device space reflect a mix of incumbent manufacturers with broad portfolios, specialized innovators focused on discrete device classes, and contract manufacturers that enable scale or rapid iterations. Incumbents often leverage established clinical relationships, broad distribution networks, and post-market surveillance capabilities to sustain preference among health systems, while niche players concentrate on design differentiation such as low-profile implantable ports, advanced catheter coatings, or compact elastomeric pump form factors that address clinician and patient pain points. Contract manufacturers and assembly partners play a pivotal role in accelerating time-to-market by providing regulatory-compliant manufacturing environments and supply chain continuity.
Strategic alliances between device companies, infusion therapy service providers, and digital health vendors are emerging to create integrated solutions that combine hardware, consumables, and cloud-enabled monitoring. At the same time, regulatory compliance and quality management remain decisive competitive levers; firms that demonstrate robust safety performance, transparent post-market data, and streamlined regulatory submissions gain credibility with procurement committees. Overall, competitiveness derives less from single-product superiority and more from the ability to deliver comprehensive, supportable, and economically viable solutions across clinical pathways.
Actionable strategic priorities for device makers and healthcare providers to accelerate adoption, strengthen supply chains, and enhance long-term competitiveness
Industry leaders must pursue a set of coordinated actions to translate technological progress and market signals into sustained commercial advantage. First, align product development with real-world clinical workflows by investing in human factors research and clinician co-design efforts; devices that fit seamlessly into nursing routines and caregiver tasks reduce training burden and accelerate adoption. Second, prioritize supply chain resilience through supplier diversification, strategic inventory buffers for critical components, and scenario-based contingency planning to withstand trade disruptions and material shortages.
Third, embed connectivity and cybersecurity by design, ensuring that devices offer secure telemetry and interoperability while meeting patient privacy expectations and regulatory requirements. Fourth, adopt flexible commercialization models that combine capital sales with service or managed-use offerings, enabling providers to control upfront costs while benefitting from ongoing maintenance and analytics. Fifth, engage early with regional regulatory authorities to streamline approvals and align post-market surveillance programs with local expectations. Taken together, these actions create a defensible value proposition and reduce commercial risk while positioning organizations to respond to evolving clinical and policy environments.
A robust mixed-methods research design integrating stakeholder interviews, observational validation, regulatory review, and supply chain mapping for rigorous insights
The research methodology underpinning this analysis combines primary stakeholder engagement, comprehensive secondary review, and structured synthesis to ensure rigor and relevance. Primary research involved qualitative interviews with clinicians, procurement leaders, regulatory specialists, and device engineers to capture frontline perspectives on usability, failure modes, and procurement decision criteria. These insights were supplemented by observational assessments of infusion workflows and device handling practices to validate reported pain points and to identify latent design needs.
Secondary research encompassed regulatory documentation, standards guidance, patent landscapes, and clinical literature to map safety requirements, technological trajectories, and evidence expectations. Data triangulation techniques reconciled differing inputs, enabling the identification of consistent themes and outliers. The methodology also incorporated supply chain mapping and risk assessment to evaluate sourcing exposure and logistics constraints. Throughout, quality controls included expert peer review, traceability of primary data sources, and iterative validation with independent subject matter experts to ensure that conclusions reflect both empirical observation and domain expertise.
Concluding synthesis that connects device innovation, supply chain resilience, and regulatory strategy to long-term clinical and commercial value creation
In conclusion, the chemotherapy device ecosystem is in a period of constructive disruption driven by clinical decentralization, device connectivity, and supply chain recalibration. These forces create opportunities for product innovation that prioritizes patient safety, clinician usability, and flexible deployment across ambulatory, homecare, and institutional settings. Trade-related developments have added urgency to supply chain strategy and sourcing decisions, prompting firms to evaluate localization, supplier diversification, and contract structures as means to preserve continuity and margin.
Decision-makers who combine human-centered design, integrated digital capabilities, and proactive regulatory engagement will be best positioned to translate technical advances into sustained clinical and commercial value. By focusing on resilient operations and solution-oriented commercialization, manufacturers and providers can adapt to current headwinds and capitalize on the evolving modalities of cancer care to deliver safer, more accessible infusion therapies.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Advancements in closed-loop infusion pumps for real-time monitoring of chemotherapy drug delivery
- 5.2. Growing adoption of wearable ambulatory infusion systems for outpatient oncology care
- 5.3. Integration of AI-enabled dose adjustment algorithms into chemotherapy delivery devices
- 5.4. Development of connected smart catheter systems to reduce infusion-related complications
- 5.5. Emergence of mobile chemotherapy administration platforms enabling home-based cancer treatment
- 5.6. Collaboration between device manufacturers and biopharma for personalized chemo dosing solutions
- 5.7. Impact of evolving regulatory guidelines on safety validation of advanced chemotherapy infusion devices
- 5.8. Surge in demand for single-use disposable infusion sets to minimize cross-contamination risks and lower sterilization costs
- 5.9. Advancements in ultrasonic flow meters to enable precise low-volume chemotherapy dosing in pediatric oncology patients
- 5.10. Rising interest in low-shear flow control modules to preserve chemotherapy agent stability during administration
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Chemotherapy Device Market, by Product Type
- 8.1. Catheters
- 8.1.1. Central Venous Catheters
- 8.1.2. Peripheral Catheters
- 8.2. Implantable Ports
- 8.3. Infusion Pumps
- 8.3.1. Elastomeric Pumps
- 8.3.2. Syringe Pumps
- 8.3.3. Volumetric Pumps
- 8.4. Needleless Connectors
- 9. Chemotherapy Device Market, by Modality
- 9.1. Portable Devices
- 9.2. Stationary Devices
- 10. Chemotherapy Device Market, by Application
- 10.1. Breast Cancer
- 10.2. Colorectal Cancer
- 10.3. Leukemia
- 10.4. Lung Cancer
- 10.5. Prostate Cancer
- 11. Chemotherapy Device Market, by End User
- 11.1. Ambulatory Surgical Centers
- 11.2. Homecare Settings
- 11.3. Hospitals & Clinics
- 12. Chemotherapy Device Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Chemotherapy Device Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Chemotherapy Device Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. ACE Medical Co., Ltd.
- 15.3.2. AngioDynamics, Inc.
- 15.3.3. Arcomed AG
- 15.3.4. Avanos Medical, Inc.
- 15.3.5. B. Braun SE
- 15.3.6. Baxter International Inc.
- 15.3.7. Becton, Dickinson and Company
- 15.3.8. Cardinal Health, Inc.
- 15.3.9. CODAN Medizinische Geräte GmbH
- 15.3.10. Districlass Médical SA
- 15.3.11. ICU Medical, Inc.
- 15.3.12. InfuSystems, Inc.
- 15.3.13. Intera Oncology Inc. by Boston Scientific Corporation
- 15.3.14. Leventon S.A.U. by Werfen, S.A.
- 15.3.15. Medtronic plc
- 15.3.16. Micrel Medical Devices SA
- 15.3.17. Mindray Medical International Limited
- 15.3.18. Nipro Corporation
- 15.3.19. Poly Medicure Limited
- 15.3.20. RenovoRx, Inc.
- 15.3.21. Shenzhen MedRena Biotech Co., Ltd.
- 15.3.22. Teleflex Incorporated
- 15.3.23. Terumo Corporation
- 15.3.24. ThermaSolutions Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
